Mycophenolate After Stem Cell Transplant for Systemic Sclerosis
Key facts
- Where
- Ottawa, KanadaSee the site
- Phase
- 2. fázis
Where in Kanada
- The Ottawa HospitalOttawa, KanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Hospital Research Institute
- Trial code
- NCT07734012
- Record updated
- 2026. október 19.
- Original description
A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible .Read full original descriptionShow less
Immunomodulatory Maintenance Therapy Post-Autologous Hematopoietic Stem Cell Transplantation for Prevention of Systemic Sclerosis Relapse: A Pilot Randomized Trial
A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible .
We are studying whether a brief course of treatment with MMF after AHSCT will serve to prevent disease relapse.
Inclusion: Consenting participants 18 years of age or older who are initiating AHSCT at The Ottawa Hospital for management of SSc.
Exclusion: Exclusion criteria are focused on patient safety, namely inability to receive treatment with; MMF due to contraindications as determine at time of randomization (day 90 / clinic visit #3) including:; Previously documented intolerance; Renal insufficiency (eGFR <25 mL/minute/1.73m2) or; Neutropenia (ANC <1.0 x 103/mcL) or; Thrombocytopenia (platelet count <50 000/mcL); Pregnant or breastfeeding - Women of childbearing potential who are not willing to use a highly effective method of contraception for the duration of study participation will be excluded.